Shanghai, China

Zhenyu Dai

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zhenyu Dai: Innovator in Cancer Treatment

Introduction

Zhenyu Dai is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on methods and materials that target HER2-expressing cancers, which are critical in advancing therapeutic options for patients.

Latest Patents

Zhenyu Dai holds a patent for "Methods and materials for treating cancer." This patent outlines methods and materials designed to treat mammals, including humans, suffering from HER2-expressing cancers. The patent specifically details the use of antibody drug conjugates that combine an anti-HER2 antibody with at least one molecule of an anti-cancer drug. These conjugates are administered to effectively treat patients with HER2-expressing cancers.

Career Highlights

Zhenyu Dai is associated with Shanghai Miracogen Inc., where he continues to work on groundbreaking cancer therapies. His dedication to research and innovation has positioned him as a key figure in the fight against cancer. With 1 patent to his name, he is recognized for his contributions to medical science.

Collaborations

Zhenyu Dai collaborates with notable colleagues, including Chaohong Hu and Hu Li. Their combined expertise enhances the research efforts at Shanghai Miracogen Inc. and contributes to the development of effective cancer treatments.

Conclusion

Zhenyu Dai's work in cancer treatment exemplifies the impact of innovative research on healthcare. His patent for methods and materials targeting HER2-expressing cancers represents a significant advancement in therapeutic options. Through his career at Shanghai Miracogen Inc., he continues to contribute to the field, making strides toward better treatment solutions for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…